Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | FABP7 | O15540 | 1/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31010250 | 1.00 | KMT2A (0.58) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| SCHEMBL20209153 | 1.00 | KMT2A (0.58) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| SCHEMBL19960742 | 1.00 | KMT2A (0.58) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| SCHEMBL15160679 | 1.00 | KMT2A (0.58) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| Hydrochloric Acid SCHEMBL21460614 | 0.99 | KMT2A (0.57) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| Hydrochloric Acid SCHEMBL16742394 | 0.99 | KMT2A (0.57) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| Hydrochloric Acid SCHEMBL30387296 | 0.99 | KMT2A (0.57) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| SCHEMBL30341663 | 0.99 | KMT2A (0.59) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| SCHEMBL2254751 | 0.99 | KMT2A (0.59) | KMT2AEPHX2SMN1; SMN2LMNATLR2 | |
| Hydrochloric Acid SCHEMBL5579268 | 0.97 | KMT2A (0.58) | KMT2AEPHX2SMN1; SMN2LMNATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705299-A1 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | Rayzebio, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20240409573-A1 | CALICHEAMICIN DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | PFIZER INC. (US) | 2024-12-12 | — | — | US | disclosed |
| WO-2024229154-A1 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING CARBONIC ANHYDRASE IX AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| US-11993625-B2 | Calicheamicin derivatives and antibody drug conjugates thereof | PFIZER, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-20230173082-A1 | ANTIBACTERIAL PRODUCTS | UNIVERSITY OF LINCOLN (GB) | 2023-06-08 | — | — | US | disclosed |
| US-11660350-B2 | Antibacterial products | UNIVERSITY OF LINCOLN (GB) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409573-A1 | CALICHEAMICIN DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF | STT3A, CLSPN, STT3B | KMT2A 3063/4885EPHX2 3031/4885SMN1; SMN2 4268/4885 |
| US-11660350-B2 | Antibacterial products | MSN, VAPA, SLC47A2 | KMT2A 3289/4885EPHX2 3477/4885SMN1; SMN2 2804/4885 |
| US-11993625-B2 | Calicheamicin derivatives and antibody drug conjugates thereof | STT3A, CLSPN, STT3B | KMT2A 3063/4885EPHX2 3031/4885SMN1; SMN2 4268/4885 |
| US-20230173082-A1 | ANTIBACTERIAL PRODUCTS | XIAP, CLSPN, SLC47A2 | KMT2A 4141/4885EPHX2 2807/4885SMN1; SMN2 2914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.